PCM
NAGE

Pinz Capital Management’s Niagen Bioscience NAGE Stock Holding History

Pinz Capital Management’s Portfolio NAGE Stock Details NAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-12,100
Closed -$119K – 417
2021
Q2 		$119K Buy
+12,100
New +$106K 0.04% 177

Other funds holding NAGE

YRHAM
Yong Rong (HK) Asset Management Sheung Wan, Hong Kong $227M AUM 300.38% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
IC
Iconiq Capital San Francisco, California $4.46B AUM 22.86% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
UIC
Uniplan Investment Counsel Milwaukee, Wisconsin $974M AUM 21.37% 1-Year Est. Return

Pinz Capital Management's NAGE Position: Q3 2021 in Review

Pinz Capital Management sold out of Niagen Bioscience (NAGE) in Q3 2021, closing a stake of 12,100 shares — an estimated $119K sold.

Pinz Capital Management first reported a position in NAGE in Q2 2021 and held it in 1 quarter. The position peaked at $119K in Q2 2021. 86 funds tracked by Wall St. Rank hold NAGE as of Q3 2021.

  • Pinz Capital Management reported no remaining Niagen Bioscience position as of Q3 2021 after selling out during the quarter.
  • Pinz Capital Management sold 12,100 Niagen Bioscience shares in Q3 2021, an estimated $119K.
  • Pinz Capital Management first reported a position in Niagen Bioscience in Q2 2021 and held it in 1 quarter.
  • Pinz Capital Management's Niagen Bioscience position peaked at $119K in Q2 2021.
  • 86 funds tracked by Wall St. Rank held Niagen Bioscience as of Q3 2021.

Based on Pinz Capital Management's 13F filing for Q3 2021, filed 15 Nov 2021.